Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Kit for predicting, preventing and treating myopia

A kit and myopia technology, applied in the biological field, to achieve the effect of good diagnosis and treatment, improve acceptance, and reduce the burden of treatment

Pending Publication Date: 2022-04-22
JINSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (EYE DISEASE PREVENTION & TREATMENT CENT OF JINSHAN DISTRICT RES CENT FOR CHEM INJURY EMERGENCY & CRITICAL MEDICINE OF SHANGHAI MUNICIPAL HEALTH COMMISSION)
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

About a kind of prediction of the present invention, the test kit of preventing and treating myopia has not yet been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for predicting, preventing and treating myopia
  • Kit for predicting, preventing and treating myopia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1 clinical experiment

[0025] 1 method

[0026] The clinical subjects recruited into the group were subjected to subjective refraction with a comprehensive refractometer and axial length measurement with an IOL-master, and the tears were collected with Schirmer test paper (collection time was 5 minutes) and then quickly immersed in 500 μL of protein lysate (BC3710; Beijing Suolaibao Technology Co., Ltd., China) EP tube, and stored at -20 ° C, followed by ELISA method to detect the concentration of AREG protein in each sample.

[0027] Inclusion criteria: age 18-40 years old, corrected visual acuity 1.0, anisometropia ≤ 1.50D

[0028] Exclusion criteria: systemic diseases, long-term medication history, eye surgery history, ocular surface diseases, eye inflammation, laser surgery, etc.

[0029] Grouping: myopia group (equivalent spherical lens -0.5 to -6.0D)

[0030] Emmetropic group (equivalent spherical lens +0.5 to -0.5D)

[0031] Inspection method: Mea...

Embodiment 2

[0042] Embodiment 2 animal experiments

[0043] 1 method

[0044] 2-week-old male tricolor guinea pigs were divided into normal group and myopia group. In the myopia group, guinea pigs in the myopia group were covered with the right eye to induce form-deprivation myopia (FDM). Starting from the third week of the cover, the AREG antibody (FDM+ anti-AR), AREG exogenous protein (FDM+AR), PBS (FDM+vehicle), once a week, continuous injection for 2 weeks, the diopter and axial length of each group were measured before and after the experiment.

[0045] FDM model induction method: 2-week-old male three-color guinea pigs were raised in a natural light environment. The guinea pigs wore a headgear made of translucent balloons to cover the right eye. Movements such as head rotation are not affected.

[0046] Measurement of biological parameters: After instilling tropicamide eye drops 4 times at intervals of 5 minutes, the guinea pigs were subjected to a strip photoretinoscopy (YZ24; Suzh...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a kit for predicting, preventing and treating myopia. The kit comprises a reagent for detecting tear AREG content and / or an AREG antibody. The invention provides a myopia evaluation marker, and clinical experiments show that the tear AREG concentration of a myopia patient is obviously higher than that of a non-myopia group, and the tear AREG concentration is in obvious negative correlation with an equivalent spherical lens; significant positive correlation is formed with the eye axis length; and obvious positive correlation is formed with the axial ratio. An FDM (fused deposition modeling) model shows that myopia development can be inhibited by injecting the AREG antibody in a glass cavity, and exogenous AREG is supplemented to promote myopia development. The method has the advantages that the tears serve as detection specimens for the first time, whether the patient is shortsighted or not can be predicted by detecting the AREG content in the tears, and compared with the prior art, the method is easy and convenient to operate, capable of achieving non-invasive detection and treatment, better in effect and good in application prospect.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a kit for predicting and preventing myopia. Background technique [0002] Myopia is a kind of refractive error in which external objects are imaged in front of the retina caused by the mismatch between the growth and development of the eye axis and the refractive power of the eyeball. The growth and development of the eyeball is inseparable from the secretion of signaling molecules and the activation and regulation of related signaling pathways. At present, the monitoring of the degree of myopia mainly relies on physical measurement methods of biological parameters such as axial length, diopter, and fundus conditions. There is no clear molecular marker related to the degree of myopia that has been applied clinically. The retention of tear samples is a convenient, non-invasive and rapid method, which can be widely used in clinical practice. At present, there are few studies on whethe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68A61K31/7088A61K39/395A61K45/00A61P27/10
CPCG01N33/6893A61K45/00A61K31/7088A61K39/3955A61P27/10G01N2800/16G01N2333/47
Inventor 周晓东佘曼李炳
Owner JINSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (EYE DISEASE PREVENTION & TREATMENT CENT OF JINSHAN DISTRICT RES CENT FOR CHEM INJURY EMERGENCY & CRITICAL MEDICINE OF SHANGHAI MUNICIPAL HEALTH COMMISSION)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com